# New Phase 3 clinical trials: 3,721 posted since Nov 2024

Updated November 9, 2026.

3,721 clinical studies in phase 3 were first posted on ClinicalTrials.gov from November 12, 2024 to November 9, 2026; 2,047 have an industry sponsor and 2,906 are recruiting or about to. The newest, NCT07926048, was posted on November 9, 2026: A Study of QLS5132 in Platinum-Resistant Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (Qilu Pharmaceutical Co., Ltd.).

## The full list

New Phase 3 clinical trials: 3,721 rows for $117.21, first posted on ClinicalTrials.gov from November 12, 2024 to November 9, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Enrollment, Enrollment type, Location countries, Central contact, Contact phone, Contact email, Last update posted, Read on, Source. The new rows each week by email, about 166 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (central contact, contact phone, contact email, sponsor class, condition groups (MeSH), interventions and 5 more), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/phase/phase-3

SpecStream is the live web data engine for teams and agents. It reads every new study on ClinicalTrials.gov each morning, and this page is that reading. Ask for the conditions, phases or countries you follow and each new trial arrives in your sheet, CRM, Slack or agent with the sponsor, the sites and the listed contact.

- New trials: 3,721
- Industry sponsored: 2,047
- Recruiting or not yet: 2,906
- Latest posted: November 9, 2026

## Newest trials

The newest 100 of 3,721, each linked to its record. The full list holds every one with the sponsor class, interventions, start date and the central contact as the record prints it.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Countries | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 9, 2026 | NCT07926048 | A Study of QLS5132 in Platinum-Resistant Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Qilu Pharmaceutical Co., Ltd. | Phase 3 | Not yet recruiting | Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer | 420 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07926048) |
| November 9, 2026 | NCT07925398 | Hetrombopag for Thrombocytopenia in Patients Scheduled for Elective Hepatic Interventional Diagnostic and Therapeutic Procedures: A... | Zhongda Hospital | Phase 3 | Not yet recruiting | Thrombocytopenia, Hepatic Interventional Procedure | 108 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07925398) |
| November 9, 2026 | NCT07925190 | A Phase III Study Comparing Mesutoclax + Azacitidine Versus Venetoclax + Azacitidine in Untreated Acute Myeloid Leukemia (AML) Patients | Beijing InnoCare Pharma Tech Co., Ltd. | Phase 3 | Not yet recruiting | Acute Myeloblastic Leukaemia | 318 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07925190) |
| November 9, 2026 | NCT07925021 | A Study of SYS6010 Combined With Enlonstobart in Patients With Previously Systemic Treatment-Naive R/M Nasopharyngeal Carcinoma | CSPC Megalith Biopharmaceutical Co.,Ltd. | Phase 3 | Recruiting | Previously Systemic Treatment-Naive Recurrent or Metastatic Nasopharyngeal Carcinoma | 424 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07925021) |
| November 9, 2026 | NCT07924111 | A Randomized, Controlled, Double-Blind, Multicenter Phase III Clinical Trial to Evaluate the Efficacy and Safety of Enlonstobart, With or... | CSPC Megalith Biopharmaceutical Co.,Ltd. | Phase 3 | Not yet recruiting | Esophageal Squamous Cell Carcinoma | 585 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07924111) |
| November 9, 2026 | NCT07924059 | Phase 3 Clinical Trial Evaluating the Efficacy and Safety of Navepegritide and Lonapegsomatropin in Achondroplasia | Ascendis Pharma A/S | Phase 3 | Not yet recruiting | Achondroplasia | 144 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07924059) |
| November 9, 2026 | NCT07923981 | A Study to Assess the Safety of Marstacimab and How Well it Works in People With Mild to Moderate Hemophilia A or B Without Inhibitors | Pfizer | Phase 3 | Recruiting | Hemophilia A or B | 95 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07923981) |
| November 6, 2026 | NCT07922863 | MUTTON-HF Pilot Expansion | University of Pennsylvania | Phase 3 | Not yet recruiting | Heart Failure | 100 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07922863) |
| November 6, 2026 | NCT07922460 | Anti-VEGF Versus Prompt Laser or Observation for Proliferative Sickle Cell Retinopathy (ALPS) | University of Illinois Chicago | Phase 3 | Not yet recruiting | Proliferative Sickle Cell Retinopathy | 50 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07922460) |
| November 6, 2026 | NCT07922330 | A Study to Evaluate the Effectiveness and Safety of the Drug AZD6234 for Managing Weight in Adults Who Are Obese or Overweight. These... | AstraZeneca | Phase 3 | Not yet recruiting | Obesity, Overweight, Type 2 Diabetes Mellitus | 330 | China, India | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07922330) |
| November 6, 2026 | NCT07920939 | Efficacy and Safety of Once-Weekly SHR-3167 Compared With Once-Daily Insulin Glargine in Adults With Insulin-Naive Type 2 Diabetes | Jiangsu HengRui Medicine Co., Ltd. | Phase 3 | Not yet recruiting | Type 2 Diabetes | 450 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07920939) |
| November 5, 2026 | NCT07919938 | Submucosal Cryotherapy and Anti-inflammatory Drugs for Postoperative Pain Following Root Canal Treatment in Maxillary Molars | Suez Canal University | Phase 3 | Not yet recruiting | Pulpitis | 90 | Egypt | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07919938) |
| November 5, 2026 | NCT07919899 | Pharmacokinetics, Immunogenicity and Safety of Subcutaneous Dupilumab and Berahyaluronidase Alfa (ALT-B4) Coformulation | Sanofi | Phase 3 | Not yet recruiting | Dermatitis Atopic | 150 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07919899) |
| November 5, 2026 | NCT07919886 | Evaluation of the Efficacy and Safety of Fractional CO₂ Laser With and Without Intradermal Botulinum Toxin A in the Treatment of... | Cairo University | Phase 3 | Not yet recruiting | Acne, Acne Papulopustulosa | 24 | Egypt | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07919886) |
| November 5, 2026 | NCT07919678 | A Study to Learn About Study Medicine Called Berobenatide in Adults With Knee Pain and Overweight or Obesity (VESPER-OA 1) | Pfizer | Phase 3 | Recruiting | Obesity, Overweight, Osteoarthritis of the Knee | 656 | Canada, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07919678) |
| November 5, 2026 | NCT07919405 | A Research Study to Investigate How Well the Medicine CagriSema Lowers High Blood Pressure in People Living With High Blood Pressure and... | Novo Nordisk A/S | Phase 3 | Not yet recruiting | Hypertension, Obesity | 1,408 | Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, Denmark, Germany... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07919405) |
| November 5, 2026 | NCT07918846 | A Clinical Study Testing Enicepatide in Participants Living With Overweight or Obesity and Cardiovascular Disease | Hoffmann-La Roche | Phase 3 | Not yet recruiting | Overweight, Obesity, Cardiovascular Disease | 8,200 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07918846) |
| November 5, 2026 | NCT07918222 | Sequential Treatment Approaches for Treatment-Resistant Schizophrenia | Shanghai Mental Health Center | Phase 3 | Recruiting | Treatment-resistant Schizophrenia | 300 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07918222) |
| November 5, 2026 | NCT07917806 | A RCT of Collagen Scaffold for the Repair of Talus Cartilage Injury | Beijing Jishuitan Hospital | Phase 3 | Enrolling by invitation | Cartilage Defects, Talus Osteochondral Defect | 40 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07917806) |
| November 4, 2026 | NCT07917507 | A Study to Assess the Efficacy of Two Brushing Regimens in the Reduction of Established Dental Plaque and Gingivitis | Colgate Palmolive | Phase 3 | Active not recruiting | Plaque, Gingivitis | 84 | Dominican Republic | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07917507) |
| November 4, 2026 | NCT07917468 | Sintilimab Combined With LCCRT Followed by Capeox Chemotherapy in pMMR/MSS/MSI-L Locally Advanced Rectal Cancer | Innovent Biologics (Suzhou) Co. Ltd. | Phase 3 | Not yet recruiting | Locally Advanced Rectal Cancer | 500 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07917468) |
| November 4, 2026 | NCT07917247 | Safety and Efficacy of Secukinumab Versus Mycophenolate Mofetil in Relapsing Myelin Oligodendrocyte Glycoprotein Antibody-associated... | Chinese PLA General Hospital | Phase 3 | Not yet recruiting | Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD) | 130 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07917247) |
| November 4, 2026 | NCT07917143 | A Clinical Trial to Evaluate Efficacy and Safety of Navepegritide Versus Placebo in Children and Adolescents With Hypochondroplasia | Ascendis Pharma A/S | Phase 3 | Not yet recruiting | Hypochondroplasia | 81 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07917143) |
| November 4, 2026 | NCT07917078 | Reduced-Dose Thrombolysis in Intermediate-Risk Pulmonary Embolism With High-Risk Features | China National Center for Cardiovascular Diseases | Phase 3 | Not yet recruiting | Pulmonary Embolism | 270 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07917078) |
| November 4, 2026 | NCT07916922 | Assessment of The Potential Therapeutic Effects of Trimetazidine on Aluminium Phosphide-Induced Cardiotoxicity as an Adjuvant Therapy: A... | Ain Shams University | Phase 3 | Recruiting | Aluminum Phosphide Poisoning | 20 | Egypt | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07916922) |
| November 4, 2026 | NCT07916844 | Hepatic Arterial Infusion Chemotherapy Versus Capecitabine as Adjuvant Therapy for Resected Biliary Tract Cancer | Zhai Wenlong | Phase 3 | Not yet recruiting | Biliary Tract Cancer, Cholangiocarcinoma, Gallbladder Cancer | 90 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07916844) |
| November 4, 2026 | NCT07916480 | Roflumilast Cream 0.3% for Moderate to Severe Atopic Dermatitis | Arcutis Biotherapeutics, Inc. | Phase 3 | Recruiting | Atopic Dermatitis, Atopic Dermatitis (AD), Atopic Dermatitis (Eczema) | 415 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07916480) |
| November 4, 2026 | NCT07916259 | The Study of Brave-LC LDN Treatment Trial | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 3 | Not yet recruiting | Post-acute COVID-19 Syndrome | 1,300 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07916259) |
| November 4, 2026 | NCT07915739 | Internal Mammary Node Irradiation After Neoadjuvant Systemic Therapy for Breast Cancer | Mahidol University | Phase 3 | Not yet recruiting | Breast Neoplasms | 1,760 | Thailand | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07915739) |
| November 4, 2026 | NCT07915609 | A Study to Learn About Berobenatide Given Once Weekly in Adults With Knee Osteoarthritis and Overweight or Obesity With or Without Type 2... | Pfizer | Phase 3 | Recruiting | Obesity, Overweight and/or Obesity, Knee Osteoarthritis, Diabetes Melliuts, Type 2 | 756 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07915609) |
| November 4, 2026 | NCT07915518 | A Phase III Trial to Evaluate the Safety and Efficacy of Anti-inflammatory Drugs in Addition to Praziquantel in Girls and Women With Female... | Brian Ngwira | Phase 3 | Not yet recruiting | Female Genital Schistosomiasis | 800 | Côte d’Ivoire, Democratic Republic of the Congo, Ghana, Malawi | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07915518) |
| November 4, 2026 | NCT07915388 | Comparative Study of Post-Varicocelectomy Myo-inositol vs. Antioxidants vs. Surgery Alone in Infertile Men | Fayoum University Hospital | Phase 3 | Not yet recruiting | Myo-inositol, Post Varicocelectomy, Infertile Men, Varicocele | 150 | Egypt | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07915388) |
| November 4, 2026 | NCT07915219 | A Study to Learn How Well People With Bronchiectasis Tolerate Continued Treatment With Verducatib After Earlier Studies (AIRTIVITY®-ON) | Boehringer Ingelheim | Phase 3 | Not yet recruiting | Bronchiectasis | 1,500 | Argentina, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Czechia... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07915219) |
| November 4, 2026 | NCT07915037 | Evaluation of the Effect of Time of Administration on the Activity on First Line of Pembrolizumab in Association With... | Assistance Publique - Hôpitaux de Paris | Phase 3 | Not yet recruiting | Metastasic NSCLC | 254 | France | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07915037) |
| November 4, 2026 | NCT07914894 | A Study of Efficacy and Safety of FXS6837 in Anti-C5 Treated PNH Patients. | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Phase 3 | Not yet recruiting | Paroxysmal Nocturnal Hemoglobinuria | 20 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07914894) |
| November 3, 2026 | NCT07914101 | Sequential Chemotherapy Followed by Ultrahypofractionated Radiotherapy for Muscle-Invasive Bladder Cancer | Assiut University | Phase 3 | Not yet recruiting | Bladder Cancer, TURBT, Radiotherapy | 71 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07914101) |
| November 3, 2026 | NCT07913360 | GFH375 Plus Cetuximab vs Investigator's Choice of Treatment in KRAS G12D-Mutant Refractory Metastatic Colorectal Cancer | Genfleet Therapeutics (Shanghai) Inc. | Phase 3 | Not yet recruiting | Colorectal Cancer | 368 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07913360) |
| November 3, 2026 | NCT07913061 | A Study Comparing SHR-3167 With Insulin Degludec in Adults With Type 2 Diabetes Currently Treated With Basal Insulin | Jiangsu HengRui Medicine Co., Ltd. | Phase 3 | Not yet recruiting | Diabetes Mellitus, Type 2 | 680 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07913061) |
| November 3, 2026 | NCT07912970 | Tenecteplase Bridging Thrombolysis Prior to Inter-hospital Transfer for Endovascular Therapy in Anterior Circulation Large Vessel Occlusion... | Fujian Medical University Union Hospital | Phase 3 | Not yet recruiting | Acute Ischemic Stroke, Large Vessel Occlusion | 1,266 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07912970) |
| November 3, 2026 | NCT07912398 | HMPL-306 in Participants With Postoperative Residual or Recurrent Grade 2 Glioma Harboring IDH1 or IDH2 Mutations | Hutchmed | Phase 3 | Not yet recruiting | Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 Mutation | 210 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07912398) |
| November 3, 2026 | NCT07911800 | rhTPO for Thrombocytopenia in Chronic Liver Disease Patients Undergoing Elective Invasive Procedures. | MIBIO PTE. LTD. | Phase 3 | Recruiting | Thrombocytopenia Associated With Chronic Liver Disease | 150 | Georgia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07911800) |
| November 3, 2026 | NCT07911787 | Phase 3 Study of HS-10380 for Acute Schizophrenia in Chinese Adults | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Phase 3 | Not yet recruiting | SCHIZOPHRENIA 1 (Disorder) | 476 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07911787) |
| November 2, 2026 | NCT07911553 | A Study to Evaluate Surovatamig Combined With R-CHOP in Participants of 18 to \< 80 Years of Age With Previously Untreated Large B-cell... | AstraZeneca | Phase 3 | Not yet recruiting | Large B-cell Lymphoma | 1,200 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07911553) |
| November 2, 2026 | NCT07910903 | Study of CM336+CM313 Combination Therapy in Patients With Relapsed or Refractory Multiple Myeloma | Keymed Biosciences Co.Ltd | Phase 3 | Not yet recruiting | Multiple Myeloma (MM) | 320 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07910903) |
| November 2, 2026 | NCT07910760 | TRINITY TRIAL; Trial Of PRRT Plus CAPTEM Vs CAPTEM Alone In Well Differentiated GEP NETS | Tata Memorial Hospital | Phase 3 | Not yet recruiting | Gastroenteropancreatic Neuroendocrine Tumors | 123 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07910760) |
| November 2, 2026 | NCT07909902 | A Clinical Trial of Local Infiltration With Injection CZ1S for Postoperative Analgesia After Hemorrhoidectomy | Zhejiang Cuize Pharmaceutical Technology Co., Ltd. | Phase 3 | Completed | Hemorrhoids Second Degree, Hemorrhoids Third Degree, Analgesia | 243 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07909902) |
| November 2, 2026 | NCT07908875 | Upfront Lipid-Lowering Therapy With Statins Combined With Hybutimibe in Patients With Acute Ischemic Stroke or Transient Ischemic Attack. | First Affiliated Hospital of Wannan Medical College | Phase 3 | Not yet recruiting | Ischemia Stroke, TIA (Transient Ischemic Attack) | 520 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07908875) |
| November 2, 2026 | NCT07908745 | Reduced-Dose vs Standard-Dose Thoracic Radiotherapy After Induction Chemoimmunotherapy in Older or Frail Stage III NSCLC | Ruijin Hospital | Phase 3 | Not yet recruiting | Non-Small-Cell Lung Cancer | 276 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07908745) |
| November 2, 2026 | NCT07908732 | Risk-Adapted Segmental Esophagus-Sparing Radiotherapy for Definitive Non-Small Cell Lung Cancer | Ruijin Hospital | Phase 3 | Not yet recruiting | Non-Small Cell Lung Cancer | 140 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07908732) |
| November 2, 2026 | NCT07908654 | A Study to Evaluate Efficacy, Immunogenicity and Safety of a Recombinant Respiratory Syncytial Virus Vaccine in Older Adults Aged 60 Years... | Guangzhou Patronus Biotech Co., Ltd. | Phase 3 | Not yet recruiting | Respiratory Syncytial Virus (RSV), Respiratory Syncytial Virus (RSV) Infection, RSV Vaccine | 25,000 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07908654) |
| November 2, 2026 | NCT07908537 | A Clinical Trial of Gocatamig (MK-6070) With Durvalumab in Participants With Small Cell Lung Cancer (MK-6070-004) | Merck Sharp & Dohme LLC | Phase 3 | Not yet recruiting | Small Cell Lung Cancer | 564 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07908537) |
| October 30, 2026 | NCT07908082 | Aspirin for the Prevention of Ischemic Complications in Giant Cell Arteritis | Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal | Phase 3 | Not yet recruiting | Giant Cell Arteritis (GCA), Acute Coronary Syndrome (ACS), Ishemic and Thrombotic Complications | 120 | Canada | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07908082) |
| October 30, 2026 | NCT07907991 | The AIRWARD Study: A Study to Test Whether Verducatib Helps People With Chronic Obstructive Pulmonary Disease | Boehringer Ingelheim | Phase 3 | Not yet recruiting | Chronic Obstructive Pulmonary Disease | 1,800 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07907991) |
| October 30, 2026 | NCT07906717 | A Study of JNJ-101556143 With Best Supportive Care in Participants With Metastatic Prostate Cancer | Janssen Research & Development, LLC | Phase 3 | Recruiting | Prostatic Neoplasms | 400 | Israel, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07906717) |
| October 30, 2026 | NCT07906275 | INTRA-ARTERIAL MeVO TREATMENT (IMP-ACT) Within the ACT-GLOBAL Adaptive Platform Trial-NCT06352632 | University of Calgary | Phase 3 | Not yet recruiting | Stroke, Acute Ischemic, Medium Vessel Occlusion | 800 | Canada | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07906275) |
| October 29, 2026 | NCT07905183 | A Randomized Study of ELVN-001 Versus Investigator-Selected TKI, in CP-CML Previously Treated With One or More TKIs | Enliven Therapeutics | Phase 3 | Not yet recruiting | Chronic Myeloid Leukemia (CML), Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive, Chronic Phase Chronic... | 450 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07905183) |
| October 29, 2026 | NCT07904910 | Evaluation of Crisaborole 2% Versus Tacrolimus 0.1% Each Combined With Excimer Light in the Treatment of Stable Non-segmental Facial... | Cairo University | Phase 3 | Recruiting | Vitiligo, Non-Segmental Vitiligo (NSV), Stable Vitiligo | 35 | Egypt | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07904910) |
| October 29, 2026 | NCT07904533 | Efficacy and Safety of Minocycline Add-on in Patients With Neurosyphilis | Beijing Ditan Hospital | Phase 3 | Not yet recruiting | Neurosyphilis | 778 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07904533) |
| October 29, 2026 | NCT07904429 | Keverprazan-Minocycline Dual Therapy of Different Durations Versus Bismuth Quadruple Therapy for Helicobacter Pylori Eradication. | Nanjing First Hospital, Nanjing Medical University | Phase 3 | Recruiting | Helicobacter Infection | 612 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07904429) |
| October 29, 2026 | NCT07904195 | Specific Immunotherapy With Mannan-Conjugated Allergoids for HDM-Allergic Rhinitis/Rhinoconjunctivitis\_MM09-SIT-063. | Inmunotek S.L. | Phase 3 | Recruiting | Allergic Rhinitis, Allergic Rhinoconjunctivitis, Allergic Asthma | 250 | Portugal, Spain | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07904195) |
| October 29, 2026 | NCT07904156 | A Phase III Randomized Controlled Trial of Serplulimab Plus Fruquintinib as Adjuvant Therapy for High-Risk Non-Clear Cell Renal Cell... | Sun Yat-sen University | Phase 3 | Not yet recruiting | Non-Clear Cell Renal Cell Carcinoma (nccRCC) | 108 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07904156) |
| October 29, 2026 | NCT07904052 | Specific Immunotherapy With Mannan-Conjugated Allergoids for HDM-Allergic Rhinitis/Rhinoconjunctivitis. MM09-SIT-063. | Inmunotek S.L. | Phase 3 | Recruiting | Allergic Rhinitis, Allergic Rhinoconjunctivitis, Allergic Asthma | 250 | Portugal, Spain | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07904052) |
| October 29, 2026 | NCT07903506 | To Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma | Kite, A Gilead Company | Phase 3 | Not yet recruiting | Newly Diagnosed Multiple Myeloma | 750 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07903506) |
| October 29, 2026 | NCT07903272 | A Trial Comparing Ramantamig and Daratumumab (Ramantamig-D) Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Participants... | Janssen Research & Development, LLC | Phase 3 | Not yet recruiting | Multiple Myeloma | 1,000 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07903272) |
| October 29, 2026 | NCT07903194 | A Study to Evaluate the Efficacy and Safety of MG-K10 in Adults With Chronic Rhinosinusitis With Nasal Polyps | Shanghai Mabgeek Biotech.Co.Ltd | Phase 3 | Not yet recruiting | Chronic Rhinosinusitis With Nasal Polyps | 210 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07903194) |
| October 29, 2026 | NCT07902999 | HB0025-C-0301: A Study to Investigate HB0025 Combined With Chemotherapy as First-Line Treatment for Advanced or Recurrent MMR-proficient... | Shanghai Huaota Biopharmaceutical Co., Ltd. | Phase 3 | Recruiting | First-line pMMR Endometrial Cancer | 333 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07902999) |
| October 29, 2026 | NCT07902817 | A Phase 3 Blinded Study of JADE101 in Participants With Immunoglobulin A Nephropathy | Jade Biosciences, Inc. | Phase 3 | Recruiting | IgA Nephropathy (IgAN) | 480 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07902817) |
| October 29, 2026 | NCT07902791 | Sevoflurane vs. Propofol for General Anesthesia in Patients With Acute Ischemic Stroke Treated With Endovascular Therapy | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | Phase 3 | Recruiting | Acute Ischemic Stroke, Large Vessel Occlusion | 314 | Spain | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07902791) |
| October 28, 2026 | NCT07901894 | Study to Evaluate the Efficacy and Safety of Dexketoprofen / Butylscopolamine vs Dexketoprofen in Treatment of Primary Dysmenorrhea | Laboratorios Silanes S.A. de C.V. | Phase 3 | Completed | Primary Dysmenorrhea | 130 | Mexico | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07901894) |
| October 28, 2026 | NCT07901842 | Recombinant Human Prourokinase for Acute Ischemic Stroke in the Extended Window Selected by CT-Based Artificial Intelligence | Second Affiliated Hospital, Zhejiang University, School of Medicine | Phase 3 | Not yet recruiting | Acute Ischemic Stroke | 826 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07901842) |
| October 28, 2026 | NCT07901738 | Zopapogene Imadenovec for the Treatment of Recurrent Respiratory Papillomatosis in Children | Precigen, Inc | Phase 3 | Not yet recruiting | Recurrent Respiratory Papillomatosis (RRP), Juvenile-onset Recurrent Respiratory Papillomatosis, Papillomavirus... | 15 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07901738) |
| October 28, 2026 | NCT07901725 | Linvoseltamab Versus Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone (Dara-Vcd) in Adult Participants With Newly Diagnosed... | Regeneron Pharmaceuticals | Phase 3 | Not yet recruiting | Newly Diagnosed Amyloidosis, Amyloidosis Stage I-IIIA | 382 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07901725) |
| October 28, 2026 | NCT07900789 | HRS-4642 Combined With Antitumor Agents for the Treatment of Perioperative Pancreatic Cancer | Shanghai Hengrui Pharmaceutical Co., Ltd. | Phase 3 | Not yet recruiting | Systemic Treatment-naïve Pancreatic Cancer | 825 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07900789) |
| October 28, 2026 | NCT07900633 | A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular Risk | Eli Lilly and Company | Phase 3 | Not yet recruiting | Obesity, Overweight, Cardiovascular Diseases, Diabetes Mellitus, Type 2 | 3,000 | Argentina, Australia, Brazil, Canada, China, Czechia, France, Germany, Hungary... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07900633) |
| October 28, 2026 | NCT07900373 | Echinocandin Added to Standard Treatment for Severe Pneumocystis Pneumonia | McGill University Health Centre/Research Institute of the McGill University Health Centre | Phase 3 | Not yet recruiting | Pneumocystis Jirovecii Pneumonia | 416 | Canada | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07900373) |
| October 28, 2026 | NCT07900061 | Modified Short-Course Radiotherapy Combined With Tislelizumab and CAPOX for pMMR/MSS Rectal Cancer | Sir Run Run Shaw Hospital | Phase 3 | Not yet recruiting | Rectal Cancer | 210 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07900061) |
| October 27, 2026 | NCT07899307 | Metformin in Acute Ischemic Stroke | All India Institute of Medical Sciences | Phase 3 | Not yet recruiting | Acute Ischemic Stroke | 440 | India | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07899307) |
| October 27, 2026 | NCT07899164 | Efficacy of Propranolol in Traumatic Brain Injury Patients Admitted to the ICU: A Prospective, Randomized, Triple-Blind Study | Fundació d'investigació Sanitària de les Illes Balears | Phase 3 | Recruiting | Traumatic Brain Injury (TBI) Patients | 536 | Spain | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07899164) |
| October 27, 2026 | NCT07899073 | A Study to Evaluate Efficacy and Safety of HIP2602 in Erectile Dysfunction Patients | Hanmi Pharmaceutical Company Limited | Phase 3 | Recruiting | Erectile Dysfunction | 225 | South Korea | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07899073) |
| October 27, 2026 | NCT07898943 | Evaluation of the Effect of Antibiotic Prophylaxis During Lumpectomy for Breast Cancer: Prospective Randomised Double-blind Noninferiority... | University Hospital, Clermont-Ferrand | Phase 3 | Not yet recruiting | Breast Cancer, Breast Surgery, Surgical Site Infection (SSI), Surgical Site Infection Prevention | 1,600 | France | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07898943) |
| October 27, 2026 | NCT07898774 | A Study to Assess the Efficacy and Safety of Pegcetacoplan for the Prevention of Recurrent C3G or Primary IC-MPGN in Kidney Transplant... | Swedish Orphan Biovitrum | Phase 3 | Recruiting | C3 Glomerulopathy (C3G), Primary Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN), Recurrent... | 30 | Brazil, Canada, Finland, France, Germany, Italy, Saudi Arabia, Spain... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07898774) |
| October 27, 2026 | NCT07898761 | Bovine Colostrum In The Treatment Of Severe Alcohol-Associated Hepatitis | Dayanand Medical College and Hospital | Phase 3 | Completed | Alcoholic Hepatitis | 174 | India | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07898761) |
| October 27, 2026 | NCT07898462 | A Trial of Adjunctive Fludrocortisone (50mcg, 100mcg or Placebo) in Critically Ill Patients With Septic Shock Receiving Hydrocortisone... | The George Institute | Phase 3 | Recruiting | Septic Shock | 2,200 | Australia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07898462) |
| October 27, 2026 | NCT07898072 | Safety and Efficacy of Weekly Testosterone Cypionate Auto-Injector in Men With Hypogonadism | Amneal Pharmaceuticals, LLC | Phase 3 | Recruiting | Male Hypogonadism | 190 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07898072) |
| October 27, 2026 | NCT07898033 | 1 Year Recurrence After Modified en Bloc Resection (ERBT) vs Transurethral Resection (TURBT) for Large Bladder Tumors | dmitry enikeev | Phase 3 | Recruiting | NMIBC, TCC | 136 | Israel | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07898033) |
| October 27, 2026 | NCT07897630 | Suprachoroidal Bevacizumab Versus Intravitreal Bevacizumab in Diabetic Macular Edema | Khyber Teaching Hospital | Phase 3 | Enrolling by invitation | Diabetic Macular Edema (DME) | 60 | Pakistan | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07897630) |
| October 27, 2026 | NCT07897188 | ASKC202 Plus Limertinib as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC | Jiangsu Aosaikang Pharmaceutical Co., Ltd. | Phase 3 | Not yet recruiting | EGFR Activating Mutation, Non-Squamous Non-Small Cell Lung Cancer (NSCLC), MET Positive | 425 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07897188) |
| October 27, 2026 | NCT07896590 | Orelabrutinib Plus ICP 248 vs Orelabrutinib for Relapsed/Refractory Marginal Zone Lymphoma | Beijing InnoCare Pharma Tech Co., Ltd. | Phase 3 | Not yet recruiting | Relapsed/Refractory Marginal Zone Lymphoma (MZL) | 292 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07896590) |
| October 27, 2026 | NCT07896434 | A Study to Learn How Effective, Safe, and Tolerable Upadacitinib is for Young Participants With Non-segmental Vitiligo | AbbVie | Phase 3 | Not yet recruiting | Non-Segmental Vitiligo | 154 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07896434) |
| October 26, 2026 | NCT07896265 | Efficacy And Safety of Olatorepatide in Adults With Overweight or Obesity Without Diabetes | Regeneron Pharmaceuticals | Phase 3 | Not yet recruiting | Overweight or Obesity Without Diabetes | 3,000 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07896265) |
| October 26, 2026 | NCT07896005 | A Study of SHR-A1811 Combined With Adebrelimab for the First-line HER2-overexpressing Non-squamous Non-small Cell Lung Cancer | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Phase 3 | Not yet recruiting | Non Small Cell Lung Cancer | 436 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07896005) |
| October 26, 2026 | NCT07895992 | SHR-A2009 Combined With Bevacizumab in the Treatment of Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer : a... | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Phase 3 | Not yet recruiting | Non-squamous Non-small Cell Lung Cancer | 490 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07895992) |
| October 26, 2026 | NCT07895732 | Personalized Adaptive Radiotherapy for Hepatocellular Carcinoma | University Health Network, Toronto | Phase 3 | Not yet recruiting | Hepatocellular Carcinoma (HCC) | 60 | Canada | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07895732) |
| October 26, 2026 | NCT07895238 | A Study of Perioperative Adebrelimab Plus Chemotherapy Versus Adjuvant Therapy in Patients With Resectable NSCLC | West China Hospital | Phase 3 | Not yet recruiting | Non-small Cell Lung Cancer (NSCLC) | 1,088 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07895238) |
| October 26, 2026 | NCT07895082 | Quanduzhong Capsules for Primary Osteoporosis | Shanghai University of Traditional Chinese Medicine | Phase 3 | Enrolling by invitation | Primary Osteoporosis | 300 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07895082) |
| October 26, 2026 | NCT07894861 | Efficacy and Safety of Maximum Labeled Dose Luspatercept in Lower-Risk Myelodysplastic Syndromes | Institute of Hematology & Blood Diseases Hospital, China | Phase 3 | Not yet recruiting | Myelodysplastic Syndromes | 75 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07894861) |
| October 26, 2026 | NCT07894484 | Lactium Premedication to Prevent Emergence Agitation | Tanta University | Phase 3 | Recruiting | Lactium, Premedication, Emergence Agitation, Adenotonsillectomy, Dose Finding Study | 40 | Egypt | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07894484) |
| October 26, 2026 | NCT07894328 | A Phase III Clinical Study of HRS-6209 Plus Letrozole as First-line Therapy in Patients With Advanced or Metastatic Breast Cancer | Jiangsu HengRui Medicine Co., Ltd. | Phase 3 | Not yet recruiting | Breast Cancer | 1,050 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07894328) |
| October 26, 2026 | NCT07894211 | QLC5508 vs. Investigator's Choice Chemotherapy in Advanced Extrapulmonary Neuroendocrine Carcinoma | Qilu Pharmaceutical Co., Ltd. | Phase 3 | Not yet recruiting | Extrapulmonary Neuroendocrine Carcinoma | 270 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07894211) |
| October 23, 2026 | NCT07893275 | SGB for Prevention of Postop A-Fib After Cardiac SurgeryTrial | The Cleveland Clinic | Phase 3 | Not yet recruiting | Atrial Fibrillation, Postoperative Atrial Fibrillation | 60 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07893275) |

## Sponsors posting most

| Sponsor | New trials | Latest |
| --- | --- | --- |
| AstraZeneca | 61 | November 6, 2026 |
| Pfizer | 54 | November 9, 2026 |
| Eli Lilly and Company | 49 | October 28, 2026 |
| GlaxoSmithKline | 47 | October 13, 2026 |
| Sun Yat-sen University | 40 | October 29, 2026 |
| Qilu Pharmaceutical Co., Ltd. | 37 | November 9, 2026 |
| Sanofi | 37 | November 5, 2026 |
| Assistance Publique - Hôpitaux de Paris | 35 | November 4, 2026 |
| Merck Sharp & Dohme LLC | 34 | November 2, 2026 |
| Fudan University | 34 | October 16, 2026 |
| Novo Nordisk A/S | 32 | November 5, 2026 |
| Colgate Palmolive | 31 | November 4, 2026 |
| Novartis Pharmaceuticals | 31 | September 30, 2026 |
| Hoffmann-La Roche | 30 | November 5, 2026 |
| Assiut University | 30 | November 3, 2026 |
| Ain Shams University | 28 | November 4, 2026 |
| Amgen | 27 | October 13, 2026 |
| Cairo University | 25 | November 5, 2026 |
| Janssen Research & Development, LLC | 24 | October 30, 2026 |
| AbbVie | 23 | October 27, 2026 |

## Conditions

| Condition group | New trials | Latest |
| --- | --- | --- |
| [Obesity](https://specstream.ai/data/clinical-trials/condition/obesity) | 144 | November 6, 2026 |
| [Breast Neoplasms](https://specstream.ai/data/clinical-trials/condition/breast-neoplasms) | 108 | November 4, 2026 |
| [Overweight](https://specstream.ai/data/clinical-trials/condition/overweight) | 99 | November 6, 2026 |
| [Carcinoma, Non-Small-Cell Lung](https://specstream.ai/data/clinical-trials/condition/carcinoma-non-small-cell-lung) | 88 | November 2, 2026 |
| [Diabetes Mellitus, Type 2](https://specstream.ai/data/clinical-trials/condition/diabetes-mellitus-type-2) | 87 | November 6, 2026 |
| [Ischemic Stroke](https://specstream.ai/data/clinical-trials/condition/ischemic-stroke) | 79 | November 3, 2026 |
| [Prostatic Neoplasms](https://specstream.ai/data/clinical-trials/condition/prostatic-neoplasms) | 45 | October 30, 2026 |
| [Neoplasms](https://specstream.ai/data/clinical-trials/condition/neoplasms) | 44 | October 13, 2026 |
| [Multiple Myeloma](https://specstream.ai/data/clinical-trials/condition/multiple-myeloma) | 37 | November 2, 2026 |
| [Depressive Disorder, Major](https://specstream.ai/data/clinical-trials/condition/depressive-disorder-major) | 37 | August 24, 2026 |
| [Colorectal Neoplasms](https://specstream.ai/data/clinical-trials/condition/colorectal-neoplasms) | 35 | November 3, 2026 |
| [Stroke](https://specstream.ai/data/clinical-trials/condition/stroke) | 35 | October 15, 2026 |
| [Ovarian Neoplasms](https://specstream.ai/data/clinical-trials/condition/ovarian-neoplasms) | 32 | November 9, 2026 |
| [Pain, Postoperative](https://specstream.ai/data/clinical-trials/condition/pain-postoperative) | 32 | October 19, 2026 |
| [Heart Failure](https://specstream.ai/data/clinical-trials/condition/heart-failure) | 30 | November 6, 2026 |
| [Dermatitis, Atopic](https://specstream.ai/data/clinical-trials/condition/dermatitis-atopic) | 30 | November 5, 2026 |
| [Hypertension](https://specstream.ai/data/clinical-trials/condition/hypertension) | 28 | November 5, 2026 |
| [Agnosia](https://specstream.ai/data/clinical-trials/condition/agnosia) | 27 | November 2, 2026 |
| [Pain](https://specstream.ai/data/clinical-trials/condition/pain) | 27 | October 19, 2026 |
| [Alzheimer Disease](https://specstream.ai/data/clinical-trials/condition/alzheimer-disease) | 27 | August 7, 2026 |
| [Leukemia, Myeloid, Acute](https://specstream.ai/data/clinical-trials/condition/leukemia-myeloid-acute) | 26 | November 9, 2026 |
| [Pulmonary Disease, Chronic Obstructive](https://specstream.ai/data/clinical-trials/condition/pulmonary-disease-chronic-obstructive) | 26 | October 30, 2026 |
| [Renal Insufficiency, Chronic](https://specstream.ai/data/clinical-trials/condition/renal-insufficiency-chronic) | 26 | October 22, 2026 |
| [Asthma](https://specstream.ai/data/clinical-trials/condition/asthma) | 26 | October 9, 2026 |
| [Pancreatic Neoplasms](https://specstream.ai/data/clinical-trials/condition/pancreatic-neoplasms) | 25 | September 16, 2026 |

## By country

| Country | New trials | Latest |
| --- | --- | --- |
| [China](https://specstream.ai/data/clinical-trials/country/china) | 1,259 | November 9, 2026 |
| [United States](https://specstream.ai/data/clinical-trials/country/united-states) | 1,165 | November 9, 2026 |
| [Spain](https://specstream.ai/data/clinical-trials/country/spain) | 508 | November 5, 2026 |
| [France](https://specstream.ai/data/clinical-trials/country/france) | 491 | November 4, 2026 |
| [Canada](https://specstream.ai/data/clinical-trials/country/canada) | 475 | November 5, 2026 |
| [Germany](https://specstream.ai/data/clinical-trials/country/germany) | 464 | November 5, 2026 |
| [Italy](https://specstream.ai/data/clinical-trials/country/italy) | 426 | November 5, 2026 |
| [United Kingdom](https://specstream.ai/data/clinical-trials/country/united-kingdom) | 416 | November 5, 2026 |
| [Japan](https://specstream.ai/data/clinical-trials/country/japan) | 411 | November 5, 2026 |
| [Poland](https://specstream.ai/data/clinical-trials/country/poland) | 395 | November 5, 2026 |
| [Australia](https://specstream.ai/data/clinical-trials/country/australia) | 366 | November 5, 2026 |
| [South Korea](https://specstream.ai/data/clinical-trials/country/south-korea) | 355 | November 5, 2026 |
| [Brazil](https://specstream.ai/data/clinical-trials/country/brazil) | 317 | November 5, 2026 |
| [Taiwan](https://specstream.ai/data/clinical-trials/country/taiwan) | 264 | November 4, 2026 |
| [Argentina](https://specstream.ai/data/clinical-trials/country/argentina) | 262 | November 5, 2026 |
| [Belgium](https://specstream.ai/data/clinical-trials/country/belgium) | 255 | November 5, 2026 |
| [Netherlands](https://specstream.ai/data/clinical-trials/country/netherlands) | 254 | November 5, 2026 |
| [Czechia](https://specstream.ai/data/clinical-trials/country/czechia) | 232 | November 4, 2026 |
| [Hungary](https://specstream.ai/data/clinical-trials/country/hungary) | 206 | November 5, 2026 |
| [Greece](https://specstream.ai/data/clinical-trials/country/greece) | 192 | October 21, 2026 |
| [Turkey (Türkiye)](https://specstream.ai/data/clinical-trials/country/turkey-t-rkiye) | 184 | October 28, 2026 |
| [Mexico](https://specstream.ai/data/clinical-trials/country/mexico) | 173 | November 4, 2026 |
| [India](https://specstream.ai/data/clinical-trials/country/india) | 168 | November 6, 2026 |
| [Denmark](https://specstream.ai/data/clinical-trials/country/denmark) | 166 | November 5, 2026 |
| [Romania](https://specstream.ai/data/clinical-trials/country/romania) | 165 | November 4, 2026 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Condition groups are the MeSH terms ClinicalTrials.gov assigns to each study's conditions; a study with several is in several groups. Sponsor class is the register's class of the lead sponsor. The central contact is in the full list only as the record prints it.

Free to reuse with credit to SpecStream under [CC BY 4.0](https://creativecommons.org/licenses/by/4.0/).